Table 1.
xxxx
| Age, sex | Duration of HD treatment | Primary disease | Findings and results on admission | Tx | Admission day from onset (days) | Duration of hospitalization (days) | Maximum O2 inhalation during hospitalization | Outcome | Comorbidities | Smoking | Vaccination (times) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (years, month) | Severitya | BT (℃) | SpO2 (%) | CRP (mg/dl) | HRCT | ||||||||||
| 55, M | 8y, 10 m | DMN | Moderate I | 39.2 | 98 | 4.24 | GGO ( +) | REGN-COV2, CTRX | 4 | 15 | Nasal canula 1 L/min | IMP | DM, HT | ( +) | (−) |
| 50, M | 7y, 11 m | DMN | Moderate I | 39 | 99 | 2.74 | GGO ( +) | REGN-COV2 | 7 | 8 | (−) | IMP | DM, HT, glaucoma | ( +) | × 1 |
| 78, M | 1y, 5 m | DMN | Moderate I | 39.3 | 96 | 14.17 | GGO ( +) | REGN-COV2 | 3 | 8 | Nasal canula 1 L/min | IMP | DM | ex | × 2 |
| HT, glaucoma, | |||||||||||||||
| BPH | |||||||||||||||
| 71, M | 11y,10 m | DMN | Moderate I | 39.2 | 98 | 7.6 | GGO ( +) | REGN-COV2 | 3 | 12 | Nasal canula 2 L/min | IMP | DM | (−) | × 2 |
| HT, glaucoma | |||||||||||||||
| ,pAf | |||||||||||||||
| 80, M | 1y, 2 m | DMN | Mild | 36.4 | 98 | 0.11 | (−) | REGN-COV2 | 3 | 8 | (−) | IMP | DM, HT, pAf | ex | × 2 |
| Hyperuricemia, CHF | |||||||||||||||
| 38, F | 2 m | ADPKD | Moderate II | 38.3 | 100b | 2.1 | GGO ( +) | DEX | 2 | 13 | Nasal canula 1 L/min | IMP | HT | (−) | (−) |
| 71, M | 4y, 9 m | CGN | Moderate I | 39.3 | 95 | 13.75 | GGO ( +) | DEX | 2 | 36 | Mechanical ventilation (FiO2 0.6) | IMP | pAf, HT | ( +) | (−) |
| OMI | |||||||||||||||
| CHF | |||||||||||||||
| 76, M | 14y,0 m | DMN | Moderate I | 37.5 | 98 | 21.6 | GGO ( +) | VCM,CFPM | 1 | 15 | (−) | Transfer | DM, HT | ex | (−) |
| 98, F | 6y, 4 m | NSC | Moderate I | 37.1 | 93 | 11.75 | GGO ( +) | (−) | 2 | 12 | (−) | IMP | HT, OA | (−) | (−) |
| 56, M | 25y, 7 m | CGN | Moderate I | 37 | 97 | 3.69 | GGO ( +) | DEX | 2 | 18 | Nasal 1 L/min | IMP | HT, OMI | (−) | (−) |
| 75, F | 9y, 0 m | ADPKD | Moderate I | 38.5 | 99 | 8.83 | GGO ( +) | DEX | 5 | 18 | NHF (FiO2 80% 40 L) | Dead | HT, DVT | (−) | (−) |
| 86, F | 1y, 2 m | DMN | Moderate I | 37.5 | 95 | 16.42 | GGO ( +) | SBT/ABPC | 4 | 19 | (−) | Transfer | DM, HT, RA, | (−) | (−) |
| ASO, dementia | |||||||||||||||
| 82, F | 8 m | AAV | Moderate I | 36.6 | 96 | 2.91 | GGO ( +) | (−) | 7 | 26 | Nasal 1 L/min | IMP | AAV, DM | (−) | (−) |
| pAf, BA | |||||||||||||||
| 78, M | 6y, 1 m | NSC | Moderate I | 37.5 | 96 | 4.07 | GGO ( +) | DEX | 7 | 21 | Nasal 3 L/min | IMP | HT | ex | (−) |
| Nephrectomy | |||||||||||||||
| 45, M | 6y, 9 m | DMN | Moderate I | 37.7 | 97 | 3.83 | GGO ( +) | DEX | 9 | 22 | Nasal 1 L/min | IMP | DM, HL, HT | ex | (−) |
| 54, M | 7y, 4 m | DMN | Moderate I | 37.7 | 95 | 10.84 | GGO ( +) | DEX | 6 | 14 | Mask 4 L/min | IMP | DM, HT, | (−) | (−) |
| 74, F | 8y, 6 m | DMN | Mild | 36.8 | 98 | 0.09 | (−) | (−) | 9 | 9 | Nasal 1 L/min | IMP | DM, HT, HL | (−) | (−) |
| 63, F | 2y, 0 m | DMN | Mild | 36.4 | 98 | 0.15 | (−) | (−) | 1 | 11 | (−) | IMP | DM, HT | ex | (−) |
| 71, M | 5y, 4 m | IgAN | Moderate II | 39.4 | 96 b | 16.24 | GGO ( +) | DEX,CTRX | 4 | 13 | Nasal 3 L/min | IMP | HT, HL, hyperuricemia | (−) | × 2 |
| 90, F | 7 m, 0 m | DMN | Moderate I | 37.8 | 97 | 2.24 | GGO ( +) | DEX,CTRX | 5 | 23 | Nasal 1 L/min | Transfer | DM, OMI, HT, Af | (−) | × 2 |
| 57, M | 0 m | ADPKD | Moderate I | 37.9 | 96 | 0.62 | GGO ( +) | DEX, TOC | 1 | 30 | NHF(FiO2 75% 40 L) | Transfer | HT | (−) | × 1 |
| 64, M | 8y, 3 m | TIN | Moderate I | 38.2 | 100 | 8.53 | GGO ( +) | DEX, CTRX, MEPM, CAZ | 5 | 76 | Intubation(FiO2 60) | Dead | HT, BPH | (−) | (−) |
DMN diabetic nephropathy; ADPKD autosomal dominant polycystic kidney disease; CGN chronic glomerulonephritis; NSC nephrosclerosis; AAV ANCA-associated vasculitis; IgAN IgA nephritis; HRCT high-resolution computed tomography; TX treatment; CTRX ceftriaxone sodium; DEX dexamethasone; VCM vancomycin; CFPM cefepime; SBT/ABPC sulbactam/ampicillin; TOC tocilizumab; MEPM meropenem; CAZ ceftazidime; DM diabetes mellitus; HT hypertension; BPH benign prostatic hypertrophy; pAf periodic atrial fibrillation; CHF chronic heart failure; OMI old myocardial infarction; OA osteoarthritis; DVT deep vein thrombosis; RA rheumatoid arthritis; ASO atherosclerosis obliterans; AAV ANCA-associated angiitis; OMI old myocardial infarction; BA bronchial asthma; HL hyperlipemia
aThe notation of disease severity followed the Japanese diagnostic guide[8]; “mild disease” refers to cases without complications of pneumonia, “Moderate I” refers to cases with pneumonia but no need for oxygen inhalation, “Moderate II” refers to cases with pneumonia and need for oxygen inhalation, “Severe” refers to cases that require a ventilator or nasal high flow (NHF)
bThis patient was receiving nasal oxygen inhalation at 1 L/min